-transparent.png){kind=logo}
Fluorodeoxyuridine (FUdR) interferes with cellular metabolism by inhibiting thymidylate synthase. Therefore, we sought to modulate its activity with leucovorin (LV) and to identify the maximally tolerated dose given as a 5-day continuous intravenous infusion in combination with oral administration of LV at a dose of 100 mg every hour for four doses immediately preceding the start of the FUdR infusion and then every 4 h for the entire duration of FUdR treatment. Patients were evaluated at six FUdR dose levels ranging from 0.1 to 0.375 mg/kg per day. Severe or life-threatening mucositis was first observed in two of six patients treated at 0.25 mg/kg daily. Further escalation of the dose to 0.3 mg/kg per day resulted in grade 2 mucositis in four of six patients and in grade 3 mucositis in two cases. A dose of 0.375 mg/kg daily resulted in grade 3 toxicity in all three patients treated. Other types of toxicities included skin rash and hand-foot syndrome, but no hematologic toxicities were observed. Stable disease was observed in 11 of 24 evaluable patients, including 3 subjects with renal cell carcinoma. Our recommended dose for phase II trials is 0.3 mg/kg FUdR per day.
E E Vokes, and
J W Raschko, and
N J Vogelzang, and
E E Warfield, and
M J Ratain, and
J H Doroshow, and
R L Schilsky
January 1994,
Cancer chemotherapy and pharmacology,
E E Vokes, and
J W Raschko, and
N J Vogelzang, and
E E Warfield, and
M J Ratain, and
J H Doroshow, and
R L Schilsky
January 1993,
Cancer chemotherapy and pharmacology,
E E Vokes, and
J W Raschko, and
N J Vogelzang, and
E E Warfield, and
M J Ratain, and
J H Doroshow, and
R L Schilsky
January 1992,
Cancer chemotherapy and pharmacology,
E E Vokes, and
J W Raschko, and
N J Vogelzang, and
E E Warfield, and
M J Ratain, and
J H Doroshow, and
R L Schilsky
August 1990,
American journal of clinical oncology,
E E Vokes, and
J W Raschko, and
N J Vogelzang, and
E E Warfield, and
M J Ratain, and
J H Doroshow, and
R L Schilsky
November 1990,
Journal of the National Cancer Institute,
E E Vokes, and
J W Raschko, and
N J Vogelzang, and
E E Warfield, and
M J Ratain, and
J H Doroshow, and
R L Schilsky
January 1991,
Journal of clinical oncology : official journal of the American Society of Clinical Oncology,
E E Vokes, and
J W Raschko, and
N J Vogelzang, and
E E Warfield, and
M J Ratain, and
J H Doroshow, and
R L Schilsky
November 1982,
Cancer research,
E E Vokes, and
J W Raschko, and
N J Vogelzang, and
E E Warfield, and
M J Ratain, and
J H Doroshow, and
R L Schilsky
December 2003,
Cancer chemotherapy and pharmacology,
E E Vokes, and
J W Raschko, and
N J Vogelzang, and
E E Warfield, and
M J Ratain, and
J H Doroshow, and
R L Schilsky
April 2018,
American journal of clinical oncology,
E E Vokes, and
J W Raschko, and
N J Vogelzang, and
E E Warfield, and
M J Ratain, and
J H Doroshow, and
R L Schilsky
November 1996,
Clinical cancer research : an official journal of the American Association for Cancer Research,
